Paper Details

  1. Home
  2. Paper Details

Intravaginal 6.5 mg prasterone administration in postmenopausal women with overactive bladder syndrome: A pilot study.

Author: CarusoSalvatore, CianciAntonio, Di PasquaSalvatore, FioritoDebora, IngrassanoSimona, MatarazzoMaria Grazia, PanellaMarco Marzio, SarpietroGiuseppe

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

This abstract examines the impact of vaginal prasterone administration on postmenopausal women with genitourinary syndrome of menopause (GSM) and overactive bladder syndrome (OAB). The study aimed to evaluate the efficacy of prasterone in improving GSM symptoms and quality of life, as well as its impact on vaginal atrophy.
Paper Details　
Original Abstract of the Article :
The aim of this study was to evaluate the impact of vaginally prasterone administration on postmenopausal women with genitourinary syndrome of menopause (GSM) affected by overactive bladder syndrome (OAB). A secondary aim of this study was to assess the efficacy of prasterone on VVA and quality of l...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/j.ejogrb.2021.06.009

データ提供：米国国立医学図書館（NLM）

Prasterone: A Potential Oasis for Overactive Bladder in Postmenopausal Women

Postmenopausal women often face a unique set of challenges, including overactive bladder syndrome (OAB), a condition that can significantly impact quality of life. This pilot study, like a beacon in the desert, explores the potential of vaginally administered prasterone as a treatment for OAB in postmenopausal women. The researchers, like intrepid explorers seeking a solution to a challenging problem, sought to determine if prasterone could offer relief for women suffering from OAB.

A Journey Towards Improved Bladder Control

The study, while preliminary, provides promising evidence that vaginally administered prasterone may hold potential as a treatment option for OAB in postmenopausal women. The findings, while encouraging, emphasize the need for further research to confirm these initial observations.

Seeking Relief in the Desert of Menopause

This study offers hope for women struggling with OAB. The potential of prasterone to improve bladder control could provide much-needed relief and improve quality of life. However, it is crucial to consult with a healthcare professional to determine the best treatment options for individual needs.

Dr. Camel's Conclusion

The potential of prasterone to address OAB in postmenopausal women is a welcome discovery. As a researcher, I am always eager to see new approaches emerging in the field of women's health. This study, while small, points to a potentially valuable treatment avenue for a common and often distressing condition.

Date :
  1. Date Completed 2021-08-03
  2. Date Revised 2021-08-03
Further Info :

Pubmed ID

34167036

DOI: Digital Object Identifier

10.1016/j.ejogrb.2021.06.009

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.